WO2023161887 - REMIBRUTINIB FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
National phase entry:
Publication Number
WO/2023/161887
Publication Date
31.08.2023
International Application No.
PCT/IB2023/051787
International Filing Date
27.02.2023
Title **
[English]
REMIBRUTINIB FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
[French]
REMIBRUTINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE
Applicants **
NOVARTIS AG
Inventors
BHATTACHARYA, Souvik
BIETH, Bruno
CENNI, Bruno
GRAHAM, Gordon
JUHNKE, Michael
LOESCHE, Christian
RAPP, Karin
SIN, Kim-Hien
ZIERER, Jonas Benjamin
Priority Data
63/314,572
28.02.2022
US
63/369,016
21.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2886 | |
| EPO | Filing, Examination, Granting | 18000 | |
| Japan | Filing, Examination, Granting | 2678 | |
| South Korea | Filing, Examination, Granting | 3164 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
34,468
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to methods for treating and/or preventing Hidradenitis Suppurativa in a subject having such disease or condition comprising administering a therapeutically effective dose of LOU064. Also disclosed are medicaments, dosing regimens, pharmaceutical compositions, combinations, dosage forms, and kits for use in the disclosed uses and methods.[French]
La présente invention concerne des méthodes de traitement et/ou de prévention de l'hidradénite suppurée chez un sujet atteint d'une telle maladie ou affection, comprenant l'administration d'une dose thérapeutiquement efficace de LOU064. L'invention concerne également des médicaments, des schémas posologiques, des compositions pharmaceutiques, des combinaisons, des formes posologiques et des kits destinés à être employés dans les utilisations et les procédés de l'invention.